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ABSTRACT

Somatostatin (somatotropin release inhibitory factor; SRIF), is an endogenous

peptide family that controls cellular secretion and proliferation.

While SRIF's cognate

receptors and associated actions have been clearly identified in a range of tissues, such as

the endocrine, gastrointestinal and immune systems, a role in human lung physiology

remains unknown.

Using primary human bronchial smooth muscle cells (hBSMC) as a

model for studying SRIF's actions, we have investigated whether SRIF receptors are

present and functional in human bronchial smooth muscle.

Reverse transcriptase-

polymerase chain reaction (RT-PCR) analysis ofhBSMC total mRNA demonstrated the

presence of the sst, receptor subtype, providing a molecular target for SRIF action.

SRIF's functional effects on intracellular signaling were confirmed by Western blotting

with phospho-specific antibodies for the extracellular regulated kinases 1/2 (ERKl/2).

Using a nonpeptidyl sst, selective agonist, L-779,976, we demonstrated an acute

inhibition (50 ± 5%) of basal ERKl/2 phosphorylation.

In addition, L-779,976-treated

hBSMC cell membranes showed a 2.4-fold increase in tyrosine phosphatase activity,

which was abolished by the selective tyrosine phosphatase inhibitor sodium vanadate.

Furthermore, a 48 h treatment with 1 0 0 nM L-779,976 suppressed hBSMC proliferation

by 30%.

Taken together, our results show that the hBSMC is a direct target of SRIF' s

antiproliferative activity.

We propose that SRIF's actions in controlling lung smooth

muscle cell proliferation could prove therapeutically useful in chronic asthma where

inappropriate hBSMC proliferation plays a role.

Keywords: somatostatin, somatostatin receptors, inflammation, bronchial smooth muscle

cells, extracellular regulated kinase, tyrosine phosphatase.
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INTRODUCTION

Asthma, characterized by airway hyperreactivity and airway structure remodeling,

is thought to be the consequence of inflammation (Halayko and Amrani, 2003).

Among

the myriad of changes that take place within the bronchial walls of an asthmatic -

subepithelial fibrosis, epithelial detachment, mucus gland hyperplasia, sub-mucosal

myofibroblast hypertrophy, increased vascularization, and neuronal differentiation

smooth muscle hypertrophy and hyperplasia play a dominant role in asthma (Holgate,

2003; Jeffery, 2 0 0 1 ; Woodruff et al, 2004).

These changes within the walls of the

airway, along with a host of inflammatory cytokines, are implicated in the exacerbation

of airway hyperreactivity (Elias, 2000).

Clearly any change to the growth or contractile

function of airway smooth muscle would be an important contributor to the

pathophysiology of asthma.

Since the recognition that the presence of remodeled, non-specific,

hyperresponsive airways are critical to the symptomology of asthma, there has been

renewed interest in the investigation of bronchial smooth muscles cells to seek answers to

fundamental questions.

In vitro studies of airway myocytes have shown that G protein

coupled receptor (GPCR) signaling and contractile force in human bronchial smooth

muscle cells (hBSMC) can be augmented by inflammatory stimuli, both physical and

chemical in nature (Amrani et al, 2004).

In this regard, pro-inflammatory peptides such

as Substance P and Neurokinin A, have long been-accepted as contributing to the

expression of asthmatic symptoms through their ability to cause bronchoconstriction,

neurogenic edema and inflammation.

However the airway role of anti-inflammatory
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peptides, such as somatostatin (somatotropin release inhibitory factor; SRIF) has not been

explored.

SRIF, initially discovered in the hypothalamus, is a potent inhibitor of growth

hormone release (Brazeau et al, 1 9 7 3 ) .

Since then, SRIF's spectrum of biological

activities has grown steadily and today SRIF peptides are known to influence a range of

secretory functions, including gastric acid secretion (Larsson et al, 1979), thyroid

stimulating hormone effects (Singh et al, 2000), and insulin and glucagon secretion in the

pancreas (Strowski et al, 2000).

In the immune system, SRIF peptides have anti

inflammatory effects on leukocyte function (Krantic, 2000), namely SRIF inhibition of

leukocyte proliferation and cytokine synthesis (Elliot et al, 1998).

At the cellular level, SRIF peptides activate a family of five highly homologous,

G protein coupled receptors (sst, - sst-) that coexist in many tissues (Krantic et al, 2004;

Reisine, 1 9 9 5 ) .

SRIF modulates intracellular signaling by controlling membrane ion

conductance and protein phosphorylation levels, in addition to decreasing cyclic

nucleotide levels (Florio et al, 1996).

Unifying S RI F ' s cellular actions is the control of

cellular secretion and the suppression of cellular proliferation (Florio et al, 2003).

Within the body, SRIF can be found in two forms: SRIF-14 and SRIF-28,

consisting of 14 and 28 amino acids, respectively.

Additionally, cortistatin is a related

member of the SRIF peptide family, and may predominate in the immune system

(Lichtenauer-Kaligis et al, 2004).

Currently, S RI F - 1 4 is considered to be the most

widely expressed SRIF peptide and its presence can be readily detected in human serum.

While the immunomodulatory effects of SRIF may account, in part, for its anti

inflammatory properties, it is unknown whether SRIF also has direct effects on the
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bronchial smooth muscle cell, and therefore a possible role in modulating asthma.

SRIF

and receptor immunoreactivity observed in a range of lung carcinomas suggest that SRIF

may be active in lung physiology (Cattaneo et al, 1996).

Furthermore, SRIF receptors

may be up-regulated in inflammation, suggesting an immunomodulatory role for this

peptide family (Krantic, 2000).

Considering the bronchial smooth muscle cell's crucial involvement in asthma

and a possible role for SRIF peptides and receptors on bronchial smooth muscle cells, we

studied the role of SRIF and SRIF analogs on cultured human bronchial smooth muscle

cells (hBSMC).

In the current study, we show that SRIF acts through an endogenously

expressed SRIF receptor to regulate hBSMC intracellular signaling pathways that are

involved in cell proliferation.

Our results indicate a possible anti-proliferative role for

SRIF in hBSMC monolayers.
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MATERIALS AND METHODS

Cell culture

hBSMC were purchased from Clonetics (Walkersville, MD), grown in S Growth

Medium plus supplements at 37°C in the presence of 5% C02.

Cells were maintained in

2

T-75 cm

flasks, or multiwell tissue culture dishes and allowed to recover for 72 h before

the beginning of the experiment.

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

hBSMC mRNA was isolated using the Micro-FastTrack™ 2 . 0 mRNA Isolation

Kit (Invitrogen Life Technologies, CA).

cDNA synthesis and the polymerase chain reaction (PCR) were carried out using

the mRNA, the Superscript One-Step RT-PCR system (Invitrogen Life Technologies,

CA) with the appropriate oligonucleotide primer pairs (hsst1r&r-2f&r; Invitrogen Life

Technologies, CA & hsst3r&r-Sf&r; Integrated DNA Technologies, Coralville, IA).

Human

SRIF receptor primer sequences are as follows 5' to 3 ' : hsst.r =

GCAACA TGCTCA TGCC, hsst.,

= GCGTTATCCGTCCAGG; hsstir =

AGAGCCGTACTATGACCTGA, hsst-,

= AGCCACTCGGA TTCCAGAG;

hsst-, =

TCATCTGCCTCTGCTACCTGC, hsstj, = GAGCCCAAAGAAGGCAGGCT; hssta- =

CATGGTCGCT ATCCAGTGCA, hssta, = CTCAGAAGGTGGTGGTCCTG; hsst., =

GCTCCTGGTGTTCGCGGACGT, hsst.,

= GAGGATGACCACGAAGAAGTAGAGG.

RT-PCR reactions were performed in I X Reaction Mix buffer containing RT/Platinum

Taq Mix, 1 0 nM forward primer (hsstlf-sf), 1 OnM reverse primer, (hsstir-sr), template

RNA

in a

Cycler

final

volume 50

µ1.

RT-PCR was performed

96 00 (Perkin Elmer, MA) .

using

a

Samples were incubated at

Perkin Elmer

50°C

for 3 0

Thermal

min

followed
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by 94°C for 2 min and the PCR amplification was carried out over 30 cycles o f 9 4 ° C for

30 sec, 5 8 ° C for 30 sec, 72°C for 2 min, with a final extension step of 72°C for 5 min.

RT-PCR products were resolved by agarose gel electrophoresis and stained with

ethidium bromide (1 Oµg/mL).

DNA products were visualized using a UV

transilluminator (UVP, Inc., CA), and photo images were captured using Alphaimager

3 . 3 D (San Leandro, CA) computer software.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western

blotting

Parallel cultures of hBSMC cells were cultured with serum-free basal medium

(Opti-MEM, lnvitrogen Life Technologies) for 48 h an d then incubated in the presence or

absence of 1 0 0 nM SRIF-14 (Peninsula Labs, CA) for 1 5 min at 3 7 ° C .

Cell lysates were

prepared, sonicated and heated to 70°C for 1 0 min., resolved on NuPAGE 1 0 % Bis-Tris

gels (lnvitrogen Life Technologies, CA) electroblotted onto polyvinyldifluoride (PVDF)

membranes and treated for 45 min in a blocking buffer containing 5% (w/v) of non-fat

dehydrated milk.

ER.Kl/2 were immunodetected with a 1 : 1000 dilution of antiphospho

ER.Kl/2 antibodies (Cell Signaling, MA).

The membrane associated immunoreactivity

was then detected using a 1 :2000 dilution of a horseradish peroxidase-conjugated anti

rabbit secondary antibody and detected using ECL chemiluminescence (Amersham, NJ).

The resulting autoradiograph was scanned, quantified with NIH Image and expressed as

integrated pixel density, as previously described (Badway et al., 2004).

Tyrosine phosphatase assay

hBSMC cultures were incubated in the presence or absence of 1 0 0 nM SRIF-14

for 30 min.

Cell cultures were washed in PBS and then lysed in a 50mM HEPES buffer
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containing 0.5% Triton X - I O O , 10% glycerol (GibcoBRL), 2.5µM pepstatin A, 1 2 . 5 µ M

leupeptin, 1 2 . 5 µ M aprotinin, 1 2 . 5 µ M bacitracin and 200nM polymethylsulfonyl fluoride.

Lysates were centrifuged at 1 3 , 5 0 0 x g for 1 5 min at 6°C and the supernatant retained.

Protein phosphatase assays were performed in a clear bottom, black sided 96 well

dishes (Coming, Coming, NY).

hBSMC cell lysate (approximately 65µg) was incubated

with 1 OµM fluorescent phosphatase substrate, 6,8-difluoro-4-methylumberiferyll

phosphate (DiF-MUP; Molecular Probes, OR) for I O min at 3TC with intermittent

mixing in a CytoFluor 4000 fluorescent plate reader (Applied Biosystems, CA), with

360nm excitation and 460nm emission filters.

Parallel assays were conducted in the

presence of I O µM Na3V04, an inhibitor of tyrosine phosphatase activity.

The resulting

data was analyzed with GraphPad Prism 4.0 and statistical significance was determined

by analysis of variance (ANOVA), followed by a Neuman-Keuls post-test, with statistical

significance defined a s p < 0.05.

Cell viability assay

Cell viability assays were performed in 24-well plates with hBSM cells cultured

in serum-free basal medium for 24 h an d then incubated in the presence or absence of

lOOnM L779,976 for 48 hours at 37°C.

The samples were incubated with 1 µM calcein

AM for 1 5 minutes prior to analysis in a CytoFluor 4000 fluorescent plate reader

(Applied Biosystems; Blake, 2004).

The resulting data was analyzed with GraphPad

Prism 4.0 and statistical significance was determined by Student t-test (p< 0.05).

1 1

RESULTS

Analysis ofhsst receptor expression using RT-PCR

RT-PCR using SRIF receptor subtype specific oligonucleotides to analyze

hBSMC demonstrated that the human bronchial smooth muscle cells express hsst, mRNA

(Figure 1 ).

The dominant amplified product appears as a 600 base pair (hsst-) band,

indicating that the sst2 receptor subtype is present in these primary bronchial smooth

muscle cells.

While earlier studies have shown that several SRIF receptors are present in

human lung, these results are the first to demonstrate a presence of the sst, receptor

subtype in primary bronchial smooth muscle cells (Reubi et al, 2 0 0 1 ) .

A.

hsst

1

2

3

4

5

B.

600 b p 7

600bp 7

100bp7

100bp7

Figure 1.

A.

hsst2 (BSMC)

PCR amplification was performed on the s s t l - 5 receptor cDNAs.

PCR amplification ofhBSMC receptor mRNA.

B.

RT

The results are from a representative

agarose gel ofhBSMC total mRNA amplified with SRIF receptor subtype specific
oligonucleotides.

Molecular weight markers (far left lane) appear in lanes in A and B as

a 100 base pair DNA ladder.

Western blot detection of phosphorylated ERKl/2 in hBSMC

Mitogen-activated protein (MAP) kinases play a central role in mitogenesis and

differentiation, controlling both activation magnitude and duration in bronchial smooth

muscle cellular responses (Zhou and Hershenson, 2003).

We examined the activation

status of one of these protein kinases, the extracellular regulated kinases (ERKl/2) by

Western blotting experiments, using a phospho-specific antibody against ERKl/2.

In
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parallel cultures maintained under static conditions, we showed that an acute treatment

with 1 0 0 nM L-779,976 significantly decreased hBSMC basal levels of ERK.1/2

phosphorylation (Figure 2).

L-779,976 inhibited basal ERK.1/2 phosphorylation in

hBSMC by 50 ± 5% when compared to parallel, untreated controls (Figure 2, p<0.05

control versus L-779,976 treated), indicating a sst, receptor-mediated regulation of this

enzyme.

L-779,976 i n h i b i ts basal ERK1/2 phosphorylation

1 00

4 2 kD a -+ 44 l<O a -+
control

L-779,976

0
Control

Figure 2.

10·

7

M L-779,976

The sst, receptor agonist L-779,976 inhibits basal ERK.1/2 phosphorylation in

hBSMC monolayers.
absence of L-779,976.

Parallel cultures of hBSMC were incubated in the presence or
Cell lysates were resolved by gel electrophoresis, electroblotted

and incubated with antiphospho-ERK.1/2 antibodies.
using NIH Image.

Autoradiographs were quantified

The results represent the mean + SEM of three separate experiments

(p< 0.05 between control and L-779,976 treated cells; Students t-test).

The inset shows a

representative autoradiograph.

Determination of soluble tyrosine phosphatase activity

SRIF receptors can couple to the activation of phosphotyrosine phosphatases in

several cellular models, and this enzymatic activation is implicated in controlling cell

proliferation (Florio and Schettini, 1996).

To identify a possible role of the identified sst,

receptor in controlling hBSMC cellular phosphatase activity, experiments using the
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fluorescent substrate DiF-MUP were performed with hBSMC lysates prepared from

untreated and treated ( 1 0 0 nM SRIF-14) cell monolayers.

DiF-MUP provides a

fluorescent measure of protein phosphatase activity, which when combined with an

appropriate inhibitor can define the type of phosphatase activity being studied (Gee et al,

1999).

As shown in Figure 3 , 1 OOnM L-779,976 increases membrane phosphatase

activity in hBSMC monolayers by 2.4 fold over the untreated control group (p < 0.05;

control versus L-779,976), while lOOnM SRIF-14 increases membrane phosphatase

activity by 2 . 8 fold over the untreated control group (p < 0 . 0 5 ; control versus SRIF).

In

addition, co-incubation of the cell membranes with 1 0 µM sodium vanadate (Na3V04), a

potent tyrosine phosphatase inhibitor, abolished greater than 90% of the enzymatic

activity derived from both control and S RI F - 1 4 treated cells (Figure3; p < 0.05 Na3V04

versus SRIF-14 + Na3V04

).

The DiF-MUP phosphatase activity proved to be sensitive

to Na3V04 inhibition, with both control and SRIF-14 treated cell membranes

demonstrating an IC5o of inhibition in the low nanomolar concentration range (data not

shown).
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hBSWC

Membrane tyrosine phosphatase activity
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Figure 3.

SRIF ligands activate tyrosine phosphatase activity in hBSMC.

hBSMC

monolayers were either control or pretreated with 1 0 0 nM S RI F - 1 4 or L-779.976 for 1 5
min at 37°C.

Phosphatase activity was measured with 50µM DiF-MUP for 1 0 min at

3 7 ° C in a CytoFluor 4000 fluorescent plate reader.
with 1 0 µM sodium vanadate.

Parallel incubations were carried out

The results were analyzed using GraphPad Prism 3 .0 and

the data presented represent the mean + SEM of three separate experiments, each
performed in triplicate.

Determination of cell viability

To further establish S RI F - 1 4 ' s role in dampening cell proliferation, assays were

carried out in which hBSMC monolayers were incubated in the presence or absence of

lOOnM L-779,976, followed by incubation with the fluorescence viability marker,

calcein-AM.

An earlier study has shown that the number of cells present directly

correlate with the fluorescence signal as determined using a fluorescent plate reader

(Blake, 2004).

Figure 4 shows that L-779,976 treatment significantly reduced cell

numbers by approximately 30%, suggesting that the SRIF agonist effectively suppressed

hBSMC proliferation in our assay.
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hBSMC Cell Viability Assay
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10·

7

M L779, 976

L 779, 976 decreases BSMC cell number.

hBSM cells were cultured in serum

free basal medium in 24-well plates for 24 h an d then incubated in the presence or
absence of 100 nM L779, 976 for 48 hours at 37°C.

The samples were incubated with

calcein-AM for 1 5 minutes prior to analysis in a CytoFluor 4000 fluorescent plate reader
(Applied Biosystems).

L779, 976 reduced cell viability by approximately 30%.

Student

t-test, *p<0.05
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DISCUSSION

SRIF regulates intracellular signaling through actions on intracellular ion

concentrations, cyclic nucleotides and protein phosphorylation levels (reviewed in

Badway and Blake, 2005).

In our experiments we used primary human bronchial smooth

muscle cells (hBSMC) as a model system to assess SRIF-14 analogue actions, as these

cells are thought to play a significant role in asthmatic airway remodeling, a significant

component of chronic asthma (Halayko and Amrani, 2003].

We first established the SRIF receptor subtypes present in hBSMC, using RT

PCR and oligonucleotides specific to hsst.«,

The results of our RT-PCR amplification of

total hBSMC RNA clearly revealed the presence of sst2•

This finding is of considerable

interest, since our study presents the first identification of the SRIF receptor subtype

present in normal, isolated bronchial smooth muscles cells.

Although SRIF receptors can couple to multiple intracellular signaling pathways

(Badway and Blake, 2005), we were interested in examining whether the sst, receptor

could control the growth of the hBSMC.

MAP kinase activation plays a critical role in

many cellular responses including proliferation and cell cycle progression (Taille et al,

2003).

Previous studies have demonstrated a role for SRIF and SRIF analogues in

regulating MAP kinase pathways in a range of primary cells and cultured cell lines

(reviewed in Dasgupta, 2004; Badway and Blake, 2005).

In addition, it has been

demonstrated that up-regulation and therefore activation of the MAP kinase ERK.1/2

pathway can lead to the promotion of cell proliferation and cell cycle progression, and

increased cell survival thereby protecting cells from apoptosis (Chang and Karin, 2 0 0 1 ;

Werry et al, 2005).

After discovering SRIF receptor expression in hBSMC, we carried
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out western blot experiments using ERK 1 /2 phospho-specific antibodies to determine

SRIF's ability to modulate the MAP kinase pathway in hBSMC.

Since the active kinase

is phosphorylated our experiments showed that treatment with lOOnM L-779,976, the

sst2 agonist, effectively reduces the ERK phosphorylation state within hBSMCs (Figure

2).

By inference, it is possible that SRIF functions in an anti-proliferative action to

inhibit airway smooth cell expansion.

This may be an important counter regulator of the

hypertrophic response found in asthmatic airways (Zhou et al, 2004)

In vitro fluorescence assays using a synthetic substrate (DiF-MUP) explored

SRIF's intracellular signaling mechanism in hBSMC.

Treatment ofhBSMC with 100

nM L-779,976 or S RI F - 1 4 increased DiF-MUP fluorescence in prepared cell membranes.

Parallel experiments carried out in the presence of sodium vanadate, a potent tyrosine

phosphatase inhibitor, abolished the DiF-MUP activity.

These results suggest that the

measured DiF-MUP activity results from activation of soluble tyrosine phosphatases.

ERKl/2 is phosphorylated on tyrosine and threonine residues, it is possible that the

increase in tyrosine phosphatase activity as a result of sst, receptor stimulation by SRIF-

1 4 or L-779,976 treatments plays a role in the decrease in phospho-ERKl/2 levels.

MAP

kinase phosphatases (MKP), a group of dual specificity phosphatases, are members of a

superfamily of protein tyrosine phosphatases (Tonks et al, 2001 ), and our data raise the

possibility that some members of these hBSMC enzymes may be under S RI F - 1 4 control.

Since these results suggested that SRIF may function to inhibit proliferation and

hinder cell survival in hBSMC, we performed a cell proliferation assay using the

fluorescent marker calcein-AM (Blake, 2004).

After treatment with 1 OOnM L- 779 ,976

for 48 hours and subsequent calcein-AM staining, a 30% decrease in cell retained
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fluorescence was measured as compared to control, untreated cells.

Since calcein AM

retention in the cellular monolayer directly correlates with viable cell number (Blake,

2004), our results suggest that L-779,976-mediated inhibition of ERK.1/2 may have a

direct effect on hBSMC growth and proliferation.

Chronic inflammation, leading to airway remodeling and airway hyperreactivity,

is the hallmark of asthma.

The structural changes, including airway smooth muscle

hypertrophy and hyperplasia, disrupt a number of homeostatic mechanisms in the lung.

This includes disrupted homeostasis in the airway epithelium,

subepithelial fibrosis,

bronchial vascular remodeling, as well as the noted increase in airway smooth muscle

mass (McKay et al 2002).

While S RI F - 1 4 and its analogues have been shown to regulate

cellular homeostasis and exert anti-inflammatory effects in a number of cells and tissues,

the current study provides the first evidence for possible SRIF inflammatory control in

bronchial smooth muscle.

Our results have shown that a SRIF analogue is capable of regulating hBSMC

intracellular pathways that may be therapeutically important to inhibition of the structural

remodeling found in asthma.

Our results demonstrate for the first time the presence of an

sst2 receptor subtype in hBSMC, implicated in controlling distinct intracellular signaling

pathways, thereby implicating the body's endogenous SRIF peptide family in direct

actions on bronchial smooth muscle.

In order to further elucidate SRIF's anti-inflammatory effects on bronchial

smooth muscle, it would be advantageous to measure SRIF's effects on ERK.1/2

phosphorylation, tyrosine phosphatase activation, and cell viability in human bronchial

smooth muscle cells obtained from asthmatic subjects.

In addition, other intracellular
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signaling pathways, including p38 and JAK-STAT have been studied in hBSMC (Simon

et al, 2002) however, the effect of somatostatin on these kinase cascades remains to be

seen.

Such a parallel experiment would extend our knowledge of SRIF's ability to

modulate inflammation in vitro.

Ultimately, demonstration of the physiological results of

SRIF administration would provide greater insight into the future therapeutic value of

SRIF in asthma.
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CONCLUSIONS

In the current study, we establish the presence of a functionally active ssr,

receptor in human bronchial smooth muscle cells.

Our novel results show that L-779,976,

an sst, selective analogue, is capable of regulating the ERKl/2 pathway, resulting in the

deactivation of phosphorylated ERKl/2.

Our data further postulates that SRIF-treatment

causes an increase in protein tyrosine phosphatase activation, present in the membranes

ofhBSMC, which may be responsible for the dephosphorylation ofERKl/2.

Finally, we

observed that treatment with a SRIF analogue could suppress cell viability by

approximately 30%, suggesting a downregulation of hBSMC proliferation, a downstream

target of ERK 112.

These results suggest that SRIF and its analogues may play a role in

preventing the hypertrophy of the airway via intracellular signaling in human bronchial

smooth muscle cells.
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